Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. (Q38415946)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

main subject

phase II clinical trial

0 references

0 references

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Barbara Bryant

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

André Goy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Steven H Bernstein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Alice McDonald

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Michael D Pickard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Hongliang Shi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

William Trepicchio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Richard I Fisher

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Anthony L Boral

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

George Mulligan

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

1269-1277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Outcome of deferred initial therapy in mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483302

10.3109/10428194.2010.483302

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20572799%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference